EUCTR2013-004482-14-NL进行中（未招募）1 期
A phase I/II, multicenter, open-label study of EGFRmut–TKI EGF816,administered orally in adult patients with EGFRmut solid malignancies
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 211
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •For all patients (unless otherwise specified):
- •1. Written informed consent obtained prior to any screening procedures
- •2. Patient (male or female) = 18 years of age
- •3. Patients must have histologically or cytologically confirmed locally
- •advanced (stage IIIB not amendable to definitive multi-modality therapy
- •including surgery) or metastatic (stage IV) EGFR mutant NSCLC
- •AZD9291, CO-1686, or ASP8273); No more than 3 prior lines of systemic
- •antineoplastic therapies (including EGFR TKIs) in the advanced setting;
- •3rd-generation EGFR TKI treatment must be the last prior treatment
- •before study entry.
- •Other protocol-defined inclusion criteria may apply
- •4. Patients with controlled brain metastases may participate in the trial.
- •They must complete any planned radiation therapy and/or surgery > 2
- •weeks prior to the first dose of study treatment and remain
- •asymptomatic. Patients on steroids must have been on a stable low dose
- •for 2 weeks prior to initiating study treatment.
- •5. ECOG performance status: Phase I part: 0, 1, or 2; Phase II part: 0 or
- •6. Presence of at least one measurable lesion according to RECIST 1.1
- •per Investigator assessment. A previously irradiated site lesion may be
- •counted as a target lesion only if there is clear sign of progression since
- •the irradiation (see Section 14.1 Appendix 1)
- •7. Patients must be screened for HBV. Patients who are either HBsAq
- •positivie or HBVDNA positive must be willing to take antiviral therapy 1-
- •2 weeks prior to 1st dose of EGF816 treatment and continue on antiviral
- •therapy for at least 4 weeks after the last dose of EGF816.
- •8. Patients must be screened for HCV. Patients must have negative
- •hepatitis C antibody (HCV-Ab) or positive HCV-Ab but undetectable level
- •of HCV-RNA. Note patients with detectable HCV-RNA are not eligible to
- •enroll into the study.
- •9. Willingness and ability to comply with scheduled visits, treatment
- •plans, laboratory tests and other study procedures
- •10. Requirement of EGFR mutation status and prior lines of treatment for Phase I patients- (Please see section 5.2 of the protocol for more details)
- •11. Requirements of EGFR mutation status and prior lines of treatment for Phase II patients:
- •Locally advanced or metastatic NSCLC with EGFR activating mutation (e.g. L858R and/or ex19del); Who have not received any systemic antineoplastic therapy, including EGFR TKI treatment, for advanced NSCLC; Note: patients who have received no more than 1 cycle of chemotherapy in the advanced setting are allowed.
- •Other protocol-defined inclusion criteria may apply?
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 72
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 139
排除标准
- •For all patients (unless otherwise specified):
- •1. Patients with a history or presence of interstitial lung disease or
- •interstitial pneumonitis, including clinically significant radiation
- •pneumonitis (i.e. affecting activities of daily living or requiring
- •therapeutic intervention)
- •2. Patients with unstable brain metastases.
- •3. Presence or History of another malignancy
- •Exception: Patients who have been disease-free for 3 years, or patients
- •with a history of adequately treated in-situ carcinoma of the uterine
- •cervix, basal or squamous cell carcinoma, non-melanomatous cancer of
- •skin, history of stage IA melanoma that has been cured, are eligible.
- •4. Undergone a bone marrow or solid organ transplant
- •5 Known history of human immunodeficiency virus (HIV) seropositivity
- •(HIV testing is not mandatory)
- •6. Patients receiving concomitant immunosuppressive agents or chronic
- •corticosteroids use at the time of study entry except for control of brain
- •metastases, topical applications, inhaled sprays, eye drops or local
- •7. Any medical condition that would, in the investigator's judgment, prevent the patient's participation in the clinical study due to safety
- •concerns or compliance with clinical study procedures
- •8. Patients with out of range laboratory values defined as:
- •Absolute Neutrophil Count (ANC) < 1.5 x 10^9/L (1.5 x 103/µL)
- •Hemoglobin (Hgb) < 9 g/dL
- •Platelets < 75 x 10^9/L
- •Total bilirubin >1.5 x ULN. For patients with Gilbert's syndrome total
- •bilirubin >3.0 x upper limit of normal (ULN)
- •Aspartate aminotransferase (AST) and/or alanine aminotransferase
- •(ALT) >3 x ULN for patients without hepatic metastasis. AST and/or ALT
- •>5 x ULN for patients with hepatic metastasis
- •Alkaline phosphatase (ALP) > 5 xULN
- •Fasting plasma glucose > 175 mg/dL (> 9.8 mmol/L)
- •Measured or calculated creatinine clearance < 45 mL/min (0.75 mL/sec)
- •9. Patients with electrolytes outside the laboratory normal limits that
- •cannot be corrected with supplements during screening:
- •Potassium
- •Magnesium
- •Phosphorus
- •Total calcium (corrected for serum albumin)
- •10. Patients receiving treatment with medications that are known to be
- •strong inhibitors or inducers of CYP3A4/5 and cannot be discontinued 1
- •week prior to the start of EGF816 treatment and for the duration of the
- •Other protocol-defined exclusion criteria may apply
研究者
相似试验
进行中（未招募）
1 期
An interventional study of oral EGF816 in adult patients with EGFRmut solid malignanciesSolid tumorsMedDRA version: 21.0Level: LLTClassification code 10049280Term: Solid tumourSystem Organ Class: 100000004864EUCTR2013-004482-14-DEovartis Pharma Services AG500
进行中（未招募）
1 期
An interventional study of oral EGF816 in adult patients with EGFRmut solid malignanciesSolid tumorsMedDRA version: 17.0Level: LLTClassification code 10049280Term: Solid tumourSystem Organ Class: 100000004864EUCTR2013-004482-14-ESovartis Farmacéutica, S.A.211
已完成
不适用
A phase I/II, multicenter, open-label study of EGFRmut-TKI EGF816, administered orally in adult patients with EGFRmut solid malignancies (CEGF816X2101)1003866610029107non-small cell lung cancerlung cancerNL-OMON52991Antoni van Leeuwenhoek Ziekenhuis5
进行中（未招募）
不适用
An interventional study of oral EGF816 in adult patients with EGFRmut solid malignanciesSolid tumorsMedDRA version: 18.0Level: LLTClassification code 10049280Term: Solid tumourSystem Organ Class: 100000004864EUCTR2013-004482-14-FRovartis Pharma AG211
进行中（未招募）
1 期
An interventional study of oral EGF816 in adult patients with EGFRmut solid malignanciesSolid tumorsMedDRA version: 19.0Level: LLTClassification code 10049280Term: Solid tumourSystem Organ Class: 100000004864EUCTR2013-004482-14-ITovartis Pharma Services AG500